Privia's CEO Just Sold 121,000 Shares for $2.7 Million
Key Points
CEO Parth Mehrotra sold 121,086 shares directly for a total of ~$2.73 million at an average price of around $22.56 per share across two days ending May 12, 2026.
This transaction represented 21.80% of Mehrotra’s direct holdings prior to the sale, reducing his direct position to 434,357 shares.
No indirect or derivative interests were involved; all shares disposed were held directly by Mehrotra.
Mehrotra retains 434,357 direct shares of Common Stock following the transaction; the cadence and elevated size reflect the shrinking capacity of his remaining direct holdings.
- 10 stocks we like better than Privia Health Group ›
Parth Mehrotra, Chief Executive Officer of Privia Health Group (NASDAQ:PRVA), reported the direct sale of 121,086 shares for a total of approximately $2.73 million in multiple open-market transactions completed on May 11, 2026, and May 12, 2026, according to an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 121,086 |
| Transaction value | $2.7 million |
| Post-transaction shares (direct) | 434,357 |
| Post-transaction value (direct ownership) | ~$9.99 million |
Transaction value based on SEC Form 4 weighted average purchase price ($22.56); post-transaction value based on the derived holdings value as of the May 12, 2026 market close.
Key questions
- How did this sale impact Mehrotra’s direct ownership in Privia Health Group?
This transaction reduced Mehrotra’s direct stake by 21.80%, bringing his direct holdings down to 434,357 shares, which equates to an estimated 0.34% of outstanding shares as of the latest available data. - Was this sale part of a pattern or a deviation from Mehrotra’s historical activity?
The 121,086 shares disposed is the largest single open-market sell event by Mehrotra on record and reflects an acceleration in sale size, which is attributable to the declining number of shares available for disposition following a series of prior transactions. - Did the transactions involve any indirect holdings, derivative securities, or option exercises?
No; according to the filing, all shares sold were held directly and there was no activity involving indirect holdings, trusts, or derivatives in this event. - What does the data suggest about the sustainability of future large sales?
With Mehrotra’s direct holdings now at 434,357 shares and no indirect or derivative positions disclosed, continued sales at this recent scale would quickly exhaust available shares, indicating that trade sizes may decrease unless additional awards or grants are made.
Company overview
| Metric | Value |
|---|---|
| Market capitalization | $2.72 billion |
| Revenue (TTM) | $2.25 billion |
| Net income (TTM) | $21.76 million |
| 1-year price change | (8.2%) |
1-year performance calculated using May 12, 2026, as the reference date.
Company snapshot
- Offers physician enablement solutions, including technology platforms, population health tools, and management services that support independent providers and medical groups.
- Generates revenue primarily through management services organization fees, technology platform subscriptions, and value-based care arrangements with payers and health systems.
- Serves independent physician practices, medical groups, health plans, and health systems across the United States.
Privia Health Group operates as a national physician-enablement company, leveraging technology and integrated services to optimize provider performance and improve patient outcomes at scale. The company's strategy centers on enabling independent physicians to thrive in both fee-for-service and value-based care environments, enhancing clinical integration and financial alignment. With a broad network and a scalable platform, Privia Health is positioned to support healthcare organizations seeking operational efficiency and improved care delivery.
What this transaction means for investors
Mehrotra’s recent share sale was pursuant to a Rule 10b5-1 trading plan, meaning the shares were sold on a predetermined scale and schedule, with some being part of a “sell to cover” transaction to satisfy tax withholding obligations. It’s an important reminder that while it can be helpful to follow the moves of company insiders, their transactions don’t necessarily translate to their conviction or material knowledge about the company and its stock.
The company reported its first-quarter financial results on May 7. Total revenue climbed more than 25% year over year as the company enjoyed strength in same-store growth and new provider additions. Later that month, Privia also announced it was entering New Jersey, in partnership with Neurology Group of Bergen County. While the practice has just 25 adult and pediatric clinicians, it brings Privia’s total coverage to 25 states.
Despite its expansion, Wall Street seems to have mixed opinions about the stock. J.P. Morgan recently lifted its price target from $33 to $45 and maintained its overweight rating. Barclays, however, recently trimmed its target to $24 from $45, maintaining its equal weight rating and pointing to concerns about provider earnings risk tied to inflation. The stock remains down about 8% year to date as of June 8. It has a trailing P/E 125.65 and a forward P/E of 23.47, according to Yahoo! Finance. Veeva Systems, a peer in the healthcare-tech space that provides cloud-based software for the life sciences and pharmaceutical industries, trades at a trailing P/E of 30.6 and a forward P/E of 19.19.
Should you buy stock in Privia Health Group right now?
Before you buy stock in Privia Health Group, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Privia Health Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $443,191!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,258,838!*
Now, it’s worth noting Stock Advisor’s total average return is 941% — a market-crushing outperformance compared to 206% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of June 8, 2026.
Sarah Sidlow has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Veeva Systems. The Motley Fool recommends Barclays Plc. The Motley Fool has a disclosure policy.
Recommended Articles
